CLINICAL TRIALS PROFILE FOR ILUMYA
✉ Email this page to a colleague
All Clinical Trials for ILUMYA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04271540 ↗ | MIcrovascular dysfuNction In Moderate-severe Psoriasis | Recruiting | Marcelo F. Di Carli, MD, FACC | Phase 4 | 2020-08-04 | Psoriasis, a common chronic inflammatory skin disease affecting approximately 2% of the population, is associated with increased cardiovascular (CV) risk. Despite the implication of inflammation in this excess risk, it remains unclear whether reducing inflammation reduces the risk of cardiac events. This study proposes to test whether Tildrakizumab, an FDA approved therapy for psoriasis that blocks IL-23 and the Th17 pathway of inflammation, improves coronary vascular function and coronary flow reserve, as measured by noninvasive imaging with cardiac positron emission tomography. In so doing, improvement in coronary vasoreactivity, endothelial function, and tissue perfusion may have beneficial effects on myocardial mechanics, left ventricular deformation and function and, ultimately, symptoms and prognosis. This research may offer novel insights into the contributors of CV risk in psoriasis and provide data to support the development of strategies to prevent cardiovascular events in psoriatic disease. |
NCT04347473 ↗ | ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. | Recruiting | Sun Pharmaceutical Industries Limited | Phase 4 | 2020-04-06 | Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment. |
NCT04347473 ↗ | ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. | Recruiting | Psoriasis Treatment Center of Central New Jersey | Phase 4 | 2020-04-06 | Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog ointment. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ILUMYA
Condition Name
Clinical Trial Locations for ILUMYA
Trials by Country
Clinical Trial Progress for ILUMYA
Clinical Trial Phase
Clinical Trial Sponsors for ILUMYA
Sponsor Name